Patents by Inventor Marie Garinot

Marie Garinot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINES AGAINST SARS-COV-2 INFECTIONS
    Publication number: 20240016918
    Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 18, 2024
    Applicant: SANOFI PASTEUR INC.
    Inventors: Natalie ANOSOVA, Salvador Fernando AUSAR, Catherine BERRY, Florence BOUDET, Danilo CASIMIRO, Roman M. CHICZ, Gustavo DAYAN, Guy DE BRUYN, Carlos DIAZGRANADOS, Tong-Ming FU, Marie GARINOT, Lorry GRADY, Sanjay GURUNATHAN, Kirill KALNIN, Nikolai KHRAMTSOV, Valérie LECOUTURIER, Nausheen RAHMAN, Sophie RUIZ, Stephen SAVARINO, Saranya SRIDHAR, Indresh K. SRIVASTAVA, James TARTAGLIA, Timothy TIBBITTS
  • Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof
    Publication number: 20230398211
    Abstract: The present invention relates to a liposome comprising a saponin, a sterol, a phospholipid and a Toll-like receptor 4 (TLR4) agonist of formula (I), to methods of preparing liposomes, to compositions comprising them and to uses thereof, and to immunogenic compositions comprising such liposomes as adjuvant.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 14, 2023
    Applicant: Sanofi Pasteur
    Inventors: Marie Garinot, Jean Haensler, Fabienne Piras, Patrick Syntin, Sophie Ruiz
  • Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
    Patent number: 11554170
    Abstract: The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 17, 2023
    Assignees: Sanofi Pasteur SA, Boehringer Ingelheim Animal Health USA Inc.
    Inventors: Guillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
  • PERTUSSIS BOOSTER VACCINE
    Publication number: 20220054615
    Abstract: The present disclosure is directed to a modified acellular pertussis booster vaccine comprising a TLR agonist and methods of using the same for inducing an immune response.
    Type: Application
    Filed: November 29, 2019
    Publication date: February 24, 2022
    Inventors: Nicolas BURDIN, Martina OCHS, Marie GARINOT, Martine CHABAUD-RIOU, Nathalie REVENEAU, Yuanqing LIU, Noelle MISTRETTA
  • Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
    Publication number: 20170360923
    Abstract: The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicants: MERIAL INC., Sanofi Pasteur
    Inventors: Guillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
  • Vaccine composition with aluminium hydroxide nanoparticles
    Patent number: 9770505
    Abstract: A vaccine composition comprising at least one antigen and one adjuvant, characterized in that the adjuvant comprises sterile-filterable nanoparticles comprising pseudo-boehmite and polyacrylate.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: September 26, 2017
    Assignee: SANOFI PASTEUR
    Inventors: Yannick Mathieu, Benedicte Lebeau, Valentin Valtchev, Joel Patarin, Marie Garinot, Jean Haensler, Elisabeth Sauzeat
  • Vaccine Composition With Aluminium Hydroxide Nanoparticles
    Publication number: 20140234422
    Abstract: A vaccine composition comprising at least one antigen and one adjuvant, characterized in that the adjuvant comprises sterile-filterable nanoparticles comprising pseudo-boehmite and polyacrylate.
    Type: Application
    Filed: July 12, 2012
    Publication date: August 21, 2014
    Applicant: SANOFI PASTEUR
    Inventors: Yannick Mathieu, Bénédicte Lebeau, Valentin Valtech, Jöel Patarin, Marie Garinot, Jean Haensler, Elisabeth Sauzeat